Last updated: September 5, 2026
Tegafur is an established oral prodrug of 5-fluorouracil (5-FU), not a conventional new drug candidate. Its commercial value depends on combination products, principally S-1, which contains tegafur, gimeracil, and oteracil, and UFT, which combines tegafur with uracil. The core tegafur molecule has limited remaining patent value because foundational composition and formulation rights are generally expired or near-expired in major jurisdictions. Current opportunities are concentrated in regional oncology markets, lifecycle formulations, combination regimens, and manufacturing economics.
S-1 remains the strongest commercial and clinical platform. It is approved in Japan and several other markets for gastric, colorectal, pancreatic, biliary tract, and other cancers, depending on jurisdiction. It has not obtained broad U.S. approval. The market outlook is stable to moderately positive in Asia but does not support a new global blockbuster forecast without a differentiated indication, delivery system, or clinical regimen.
What is tegafur and how is it used clinically?
Tegafur is an orally administered fluoropyrimidine converted in vivo to 5-FU. It produces antimetabolite activity through inhibition of thymidylate synthase and incorporation of fluorinated metabolites into RNA and DNA.
| Attribute |
Tegafur |
| Active ingredient |
Tegafur |
| Pharmacologic class |
Oral fluoropyrimidine prodrug |
| Principal active metabolite |
5-Fluorouracil |
| CAS number |
17902-23-7 |
| Main products |
S-1 and UFT |
| Principal manufacturer originator |
Taiho Pharmaceutical |
| Primary therapeutic area |
Gastrointestinal oncology |
| Key markets |
Japan, parts of Asia, Europe, selected other markets |
| U.S. status |
No broad FDA-approved tegafur product identified in Drugs@FDA through June 2024 |
| Development status |
Established product with ongoing regimen, indication, and regional development |
Tegafur’s clinical utility comes from oral administration and prolonged systemic exposure relative to bolus 5-FU. The molecule has also been used in combination with biochemical modulators designed to increase antitumor activity or reduce toxicity.
What products contain tegafur?
S-1: tegafur, gimeracil, and oteracil
S-1 is the leading tegafur-based product. Tegafur generates 5-FU, gimeracil inhibits dihydropyrimidine dehydrogenase and slows 5-FU degradation, and oteracil reduces phosphorylation of 5-FU in the gastrointestinal tract.
S-1 was approved in Japan in 1999 and subsequently expanded into additional Asian and European markets. Product names include TS-1 and Teysuno, depending on the territory and marketing authorization structure. Its strongest commercial position is in gastric cancer and other gastrointestinal tumors.
The product’s principal development advantages are:
- Oral administration.
- Established use in gastric and colorectal cancer.
- Combination compatibility with platinum agents, oxaliplatin, irinotecan, taxanes, and immunotherapy.
- Substantial Japanese and Asian clinical experience.
- A differentiated pharmacokinetic profile compared with conventional 5-FU.
UFT: tegafur and uracil
UFT combines tegafur with uracil. Uracil competitively inhibits dihydropyrimidine dehydrogenase, increasing 5-FU exposure. UFT has been used in colorectal and other gastrointestinal cancers, often with leucovorin.
UFT has a narrower current development profile than S-1. Its commercial relevance is greater in markets where oral fluoropyrimidine treatment remains established and where local reimbursement supports generic or legacy oncology products.
What is the current development status of tegafur?
Tegafur is in a lifecycle-development phase rather than a discovery or first-in-class phase. The most commercially relevant development activities involve S-1 combinations and regional label expansion.
| Development area |
Current assessment |
Commercial relevance |
| S-1 monotherapy |
Established in selected indications |
Moderate, mainly regional |
| S-1 plus platinum therapy |
Established and widely studied |
High in gastric cancer |
| S-1 plus oxaliplatin |
Clinically developed in gastrointestinal cancers |
High in Asian markets |
| S-1 plus irinotecan |
Studied in colorectal and gastric cancer |
Moderate |
| S-1 plus taxanes |
Studied in gastric and related cancers |
Moderate |
| S-1 plus immunotherapy |
Active lifecycle and combination strategy |
Potentially high, subject to trial outcomes |
| UFT plus leucovorin |
Established oral colorectal regimen in selected markets |
Low to moderate |
| Novel tegafur delivery system |
Limited publicly established commercial momentum |
Potentially high if clinically differentiated |
S-1 has also been studied in pancreatic, biliary tract, breast, head and neck, lung, and other cancers. The development thesis is strongest where oral fluoropyrimidine treatment can improve convenience or where S-1 produces a tolerability profile that permits combination therapy.
The principal clinical limitation is geographic variability. S-1 exposure and tolerability can differ by ethnicity, body size, CYP2A6 activity, renal function, and dosing schedule. Regimens developed in Japan do not automatically translate into equivalent dosing or market adoption in North America and Europe.
What is the FDA regulatory status of tegafur?
Tegafur does not have a broad standalone FDA approval for cancer treatment. UFT and S-1 have not achieved the same U.S. regulatory position as capecitabine, 5-FU, trifluridine/tipiracil, or other fluoropyrimidine products.
The absence of a broad U.S. approval reflects several factors:
- Existing U.S. treatment alternatives are established.
- S-1 requires a combination-specific safety and dosing rationale.
- U.S. development would require a commercially meaningful indication or a clinically superior regimen.
- Ethnic and pharmacokinetic differences complicate direct transfer of Asian dosing data.
- Generic oral fluoropyrimidine competition limits pricing power.
Teysuno received European authorization for specific gastrointestinal cancer indications. European availability is narrower than Japan’s, and reimbursement differs substantially by country. Regulatory status should therefore be evaluated country by country rather than treated as a single global approval.
What is the Orange Book status of tegafur?
No major U.S. Orange Book reference product based on tegafur, S-1, or UFT has been established as a broad commercial reference product through June 2024. As a result, the conventional U.S. generic pathway and Paragraph IV litigation framework has limited practical importance for tegafur.
This position differs from the European and Japanese markets, where national marketing authorizations, data exclusivity, local patents, and reimbursement decisions are more relevant than U.S. Orange Book listings.
When does tegafur lose exclusivity?
The core tegafur molecule is old and its foundational patent protection is not a material barrier to modern development. The principal product and composition patent risk is therefore concentrated in:
- Specific tegafur combinations.
- S-1 ratios and dosage forms.
- Modified-release or controlled-release formulations.
- Treatment methods for specific cancers.
- Combination regimens with platinum agents, taxanes, irinotecan, or immunotherapy.
- Manufacturing processes and impurity controls.
- Regional patents filed after the original tegafur platform patents.
Patent protection by asset type
| Asset type |
Likely status |
Strategic importance |
| Tegafur composition of matter |
Expired or commercially non-blocking in major markets |
Low |
| Basic oral tegafur formulation |
Mostly expired or vulnerable to generic competition |
Low |
| Tegafur-uracil combination |
Legacy protection largely expired |
Low to moderate |
| S-1 composition and ratio claims |
Older rights largely expired in key jurisdictions; local variation applies |
Moderate |
| S-1 method-of-use claims |
Potentially active depending on filing date and country |
Moderate |
| New combinations with immunotherapy |
Potentially active |
High |
| New dosing schedules |
Potentially active |
Moderate |
| Manufacturing and solid-state claims |
Potentially active but difficult to assess without claim charts |
Moderate |
Patent strength is therefore fragmented. A company relying only on tegafur as an active pharmaceutical ingredient has a weak exclusivity position. A company controlling a clinically validated combination, branded formulation, or region-specific method of use can retain a stronger commercial position.
Are there Paragraph IV challenges or tegafur patent lawsuits?
No major U.S. Paragraph IV dispute involving a widely marketed tegafur reference product is identified in FDA public records through June 2024. The limited U.S. regulatory footprint reduces the probability of a conventional U.S. ANDA litigation cycle.
The more relevant disputes would involve:
- National validation of S-1 or Teysuno patents.
- European opposition or revocation proceedings.
- Patent challenges against specific combination regimens.
- Manufacturing-process disputes.
- Trademark and licensing disputes involving TS-1 or Teysuno branding.
A generic company could challenge formulation or method-of-use claims, but the absence of a large U.S. reference product reduces the immediate incentive for a high-value Paragraph IV filing.
What formulations are protected by tegafur patents?
The commercially important formulation concepts include:
- Fixed-ratio S-1 capsules containing tegafur, gimeracil, and oteracil.
- Tegafur-uracil oral capsules or tablets.
- Modified-release tegafur formulations.
- Combination packs with platinum or other cytotoxic agents.
- Dosing regimens adjusted for renal impairment or toxicity management.
- Pediatric or low-dose formulations.
- Manufacturing controls that preserve content uniformity and stability.
Formulation patents can be more commercially important than API patents because oral oncology products depend on dose accuracy, stability, tolerability, and predictable exposure. Their weakness is that many can be designed around through alternative excipients, ratios, release profiles, or packaging.
How strong is the tegafur patent estate?
The estate is weak for the uncombined molecule and moderate for branded S-1 products.
Strength assessment
| Factor |
Assessment |
| Composition-of-matter protection |
Weak |
| Regulatory exclusivity |
Limited in mature markets |
| Formulation protection |
Moderate, highly jurisdiction-specific |
| Method-of-use protection |
Moderate |
| Manufacturing protection |
Moderate |
| Brand and physician familiarity |
Strong in Japan and selected Asian markets |
| U.S. blocking position |
Weak |
| Ability to support premium pricing |
Limited outside branded S-1 markets |
The strongest barrier is not a single patent. It is the combined effect of clinical familiarity, manufacturing know-how, regulatory history, physician adoption, and reimbursement access.
Which companies compete with tegafur products?
Tegafur competes with several oral and intravenous fluoropyrimidines.
| Product |
Active ingredient or platform |
Competitive position |
| Xeloda and generics |
Capecitabine |
Strong global competitor |
| 5-FU |
Fluorouracil |
Low-cost intravenous standard |
| Trifluridine/tipiracil |
TAS-102 |
Later-line colorectal and gastric cancer |
| FOLFOX and FOLFIRI |
5-FU-based regimens |
Major regimen-level competitors |
| S-1 |
Tegafur/gimeracil/oteracil |
Strongest tegafur platform |
| UFT |
Tegafur/uracil |
Mature regional competitor |
| Oxaliplatin combinations |
Regimen-level competitor |
Important in gastrointestinal cancers |
Capecitabine is the most direct global commercial comparator because it is orally administered and converted to 5-FU through a different metabolic pathway. S-1 can be favored in selected Asian settings because of clinical familiarity and regimen tolerability, but capecitabine has broader international availability and a stronger global generic ecosystem.
What licensing deals affect tegafur?
The tegafur platform has historically relied on regional licensing and commercialization arrangements rather than a single global commercialization model. Taiho Pharmaceutical has been the principal originator associated with S-1, while regional partners have supported registration, supply, distribution, or commercialization.
The strategic value of a licensing deal depends on four terms:
- Territory and indication scope.
- Control of regulatory filings.
- Supply and manufacturing rights.
- Ownership of new combination or formulation inventions.
Because S-1 is an established product, licensing economics are more likely to involve milestone payments, supply margins, and regional sales rights than large upfront payments associated with novel oncology assets.
What generic entry risks exist for tegafur?
Generic entry risk is high for basic tegafur and UFT products where local approval pathways permit substitution. Risk is lower for S-1 when the product depends on:
- A fixed combination of three active ingredients.
- Region-specific dosing.
- Physician familiarity with a branded product.
- Limited manufacturing capacity.
- Product-specific regulatory evidence.
- Method-of-use or formulation claims.
Generic competition can still reduce pricing in Japan, Europe, and other markets as patents expire and national reimbursement agencies impose reference pricing. The greatest risk is volume substitution in mature markets, not abrupt global displacement.
What is the market projection for tegafur through 2030?
A precise standalone global market size is difficult to assign because public companies generally report tegafur revenue within broader oncology or regional portfolios. S-1 and UFT sales are also reported differently across markets. The most defensible projection is directional and scenario-based.
| Scenario through 2030 |
Expected outcome |
| Base case |
Low-single-digit annual growth in Asia; flat to modest decline in mature European markets |
| Upside case |
S-1 gains from immunotherapy combinations, pancreatic cancer use, or additional regional approvals |
| Downside case |
Generic erosion, reimbursement cuts, and substitution by capecitabine or newer agents |
| U.S. case |
Limited commercial contribution without a new FDA approval |
| Global positioning |
Regional specialty oncology product rather than global blockbuster |
Base-case market drivers
- Continued use of S-1 in Japan and selected Asian markets.
- Persistent gastrointestinal cancer incidence.
- Oral treatment preference in outpatient oncology.
- Clinical familiarity among Japanese and Asian oncologists.
- Continued combination trials with platinum chemotherapy and immunotherapy.
Market constraints
- Generic competition.
- Absence of broad U.S. approval.
- Capecitabine availability.
- Limited differentiation for uncombined tegafur.
- Reimbursement pressure on mature oral oncology products.
- Toxicity and dose-adjustment requirements.
- Regional differences in CYP2A6 metabolism and treatment practice.
Revenue exposure is concentrated in S-1 rather than standalone tegafur. A company with S-1 rights can retain meaningful regional oncology revenue, while a company selling unbranded tegafur faces commodity-like pricing.
What is the most likely generic launch scenario?
The most likely scenario is gradual regional generic penetration rather than a single global launch event.
In Japan, generic or follow-on competition can pressure price while leaving branded demand intact where oncologists value established dosing and supply reliability. In Europe, substitution depends on national reimbursement and hospital procurement. In the United States, the absence of a major FDA-approved reference product makes a conventional generic launch less likely unless a sponsor first develops and obtains approval for a new tegafur product.
A differentiated U.S. launch would likely require one of the following:
- A new S-1-based indication.
- A novel oral formulation.
- A clinical advantage over capecitabine.
- A combination with an approved immunotherapy.
- A lower-toxicity regimen for patients unable to tolerate standard fluoropyrimidines.
What are the manufacturing and intellectual-property barriers?
Manufacturing barriers are moderate. Tegafur itself is a mature small molecule, but S-1 requires reliable production of three active ingredients, precise ratio control, impurity management, capsule uniformity, and stability testing.
The strongest manufacturing advantages may include:
- Validated control of gimeracil and oteracil content.
- Consistent dissolution and bioavailability.
- Scalable production of combination capsules.
- Regulatory-grade documentation.
- Reliable supply of active ingredients.
- Process controls that reduce batch variability.
These capabilities can delay entry even when core patents are expired. They do not create the same barrier as biologic manufacturing, and they are unlikely to prevent well-capitalized generic companies from entering over time.
Key Takeaways
- Tegafur is a mature fluoropyrimidine prodrug whose commercial value is concentrated in S-1 and UFT.
- S-1 is the strongest tegafur platform, particularly in Japan and other Asian markets.
- The core tegafur patent estate is weak because foundational composition protection is old.
- Remaining defensibility rests on formulations, fixed combinations, manufacturing know-how, and method-of-use claims.
- No major U.S. Orange Book or Paragraph IV opportunity is apparent through June 2024.
- The FDA pathway remains the largest geographic limitation.
- Capecitabine is the principal global oral competitor.
- The base-case outlook through 2030 is stable to moderately positive in Asia and flat to declining in mature markets.
- A meaningful growth re-rating would require new combination data, an additional approval, or a differentiated formulation.
- Tegafur is better characterized as a regional specialty oncology platform than as a global high-growth drug candidate.
FAQs
Is tegafur the same as 5-fluorouracil?
No. Tegafur is an oral prodrug that is converted into 5-FU in the body. The two products have related pharmacology but different administration, exposure, dosing, and toxicity profiles.
Is S-1 approved in the United States?
S-1 does not have broad FDA approval for routine U.S. oncology use through June 2024. Its principal regulatory and commercial markets are Japan, Asia, and selected European countries.
Does tegafur have biosimilar risk?
No. Tegafur is a chemically synthesized small molecule, so biosimilar regulation does not apply. Its competitive risk comes from generic small-molecule products and alternative fluoropyrimidine regimens.
Which tegafur product has the strongest commercial position?
S-1, containing tegafur, gimeracil, and oteracil, has the strongest commercial and clinical position. UFT is an older and more regionally limited platform.
Could tegafur become a major immuno-oncology combination partner?
It could gain value through combinations with checkpoint inhibitors or other targeted agents, but commercial success would require prospective clinical evidence, regulatory approval, and a clear advantage over capecitabine- or 5-FU-based regimens.
References
-
European Medicines Agency. (n.d.). Teysuno: EPAR - product information. https://www.ema.europa.eu/
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
-
National Cancer Institute. (n.d.). Tegafur. NCI Drug Dictionary. https://www.cancer.gov/publications/dictionaries/cancer-drug
-
Shirasaka, T. (1996). Development history and concept of an oral anticancer agent S-1. Gan To Kagaku Ryoho, 23(Suppl. 1), 1-11.
-
Taiho Pharmaceutical Co., Ltd. (n.d.). TS-1 product and clinical information. https://www.taiho.co.jp/
-
National Institute of Health Sciences, Japan. (n.d.). Pharmaceutical and Medical Devices Agency review information. https://www.pmda.go.jp/english/
